Vertex EVP gets stock award, withholds shares

Vertex Pharmaceuticals EVP and CMO Carmen Bozic received a grant of 5,375 shares of common stock as a restricted stock unit award that begins vesting on February 20, 2027.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Vertex Pharmaceuticals EVP and CMO Carmen Bozic received a grant of 5,375 shares of common stock as a restricted stock unit award that begins vesting on February 20, 2027. On the same date, 1,912 shares at $483.75 each were disposed of to cover tax withholding, leaving her with 41,516 directly owned shares.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Bozic Carmen

Role EVP and CMO

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	5,375	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	1,912	$483.75	$925K

Holdings After Transaction: Common Stock — 41,516 shares (Direct)

Footnotes (1)

F1. Restricted stock unit award that vests in installments beginning on February 20, 2027.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Vertex (VRTX) report for Carmen Bozic?

Vertex reported that EVP and CMO Carmen Bozic received a grant of 5,375 shares of common stock and disposed of 1,912 shares for tax withholding. After these transactions, she directly owned 41,516 shares of Vertex common stock.

Was the Vertex (VRTX) insider transaction by Carmen Bozic a stock award?

Yes. Carmen Bozic received a 5,375-share restricted stock unit award of Vertex common stock. According to the disclosure, this award will vest in installments beginning on February 20, 2027, reflecting equity-based compensation rather than an open-market stock purchase.

Why were 1,912 Vertex (VRTX) shares disposed of in Carmen Bozic’s Form 4?

The 1,912 shares were disposed of to satisfy tax withholding obligations. The filing identifies the transaction with code “F,” meaning payment of tax liability by delivering securities, at a price of $483.75 per share, rather than an ordinary open-market sale.

How many Vertex (VRTX) shares does Carmen Bozic own after the reported transactions?

After the reported Form 4 transactions, Carmen Bozic directly owns 41,516 shares of Vertex common stock. This figure reflects the new restricted stock unit award and the shares disposed of to cover related tax withholding obligations on February 17, 2026.

When do Carmen Bozic’s new Vertex (VRTX) restricted stock units begin vesting?

The restricted stock unit award granted to Carmen Bozic begins vesting on February 20, 2027. The footnote explains that the 5,375-share award will vest in installments starting on that date, consistent with typical long-term incentive compensation structures.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 02/19/2026 - 04:10 PM EST

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bozic Carmen

(Last)

(First)

(Middle)

C/O VERTEX PHARMACEUTICALS INCORPORATED

50 NORTHERN AVENUE

(Street)

BOSTON

02210

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP and CMO

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/17/2026		A		5,375⁽¹⁾	A	$0	43,428	D
Common Stock	02/17/2026		F		1,912	D	$483.75	41,516	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Restricted stock unit award that vests in installments beginning on February 20, 2027.

Remarks:

	/s/ Christiana Stevenson, Attorney-in-Fact	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR